UCI PFAS Health Study

摘要 这项研究以及CDC PFAS多点健康研究中的其他研究将确定 测得的全氟烷基物质和多氟烷基物质(PFAS)的血清浓度与 儿童和成人参与者的横断面健康结果的多样性。除了强制性的核心 ，这项研究将调查PFAS与每周父母报告的儿童症状的相关性 过敏、感染或哮喘在注册后收集长达一年的时间。这项研究包括社区 在加州大学欧文分校的医学中心周围，检测到社区水中的全氟辛烷磺酸 补给。暴露重建将为我们当地的流域使用具有良好特征的水文地质模型， 废水处理厂的估计源项，以及关于井混合和水分配的效用数据 估算研究区域社区水中全氟辛酸、全氟辛烷磺酸和全氟辛烷磺酸的历史浓度。型号： 估计参与者家中和工作场所的水浓度将通过以下分析进行验证 自来水样本中的全氟辛烷磺酸，并用于估计每个研究参与者的历史每月全氟辛烷磺酸剂量。 将建立全氟辛烷磺酸(PFOS)、全氟辛酸(PFOA)、 全氟农酸盐(PFNA)、全氟己烷磺酸(PFHxS)、全氟庚酸(PFHpA)和 全氟丁烷磺酸(PFBS)，并通过比较全国范围内这些PFAS的测量结果进行了验证 公共水系统中的化学物质，2013-2015年间在EPA的第三种非管制污染物下收集 根据国家生物监测计划的个人血清测量，监测规则。这些 每个参与者的药代动力学模型和估计剂量将被用来获得建模的血清PFAS 每个参与者在一段时间内的浓度。模型血清PFAS的贝叶斯药代动力学校正 对全氟辛烷磺酸暴露混合物的浓度和非参数流行病学分析也将 在适当的时候进行。 这项研究将有助于解决关键的政策问题，即是否有PFAS供水系统为人们提供服务 与水中没有全氟辛烷磺酸的检测相比，检测到的有害健康影响的风险更大。 考虑到其他已知的风险因素。它还将提供有关以下方面的有用信息 饮用水中的全氟辛烷磺酸有助于这些化学物质的总体暴露和生物监测结果 具有全国代表性的样本。

ABSTRACT This study, along with other studies in the CDC PFAS multi-site health study, will determine whether modelled and measured serum concentrations for per- and polyfluoroalkyl substances (PFAS) are associated with a variety of cross-sectional health outcomes in child and adult participants. In addition to the mandatory core protocol, this study will investigate associations of PFAS with weekly parental reports of child symptoms of allergy, infection, or asthma collected for up to one year after enrollment. The study includes communities surrounding the Medical Center at the University of California, Irvine, with PFAS detections in community water supplies. Exposure reconstruction will use well-characterized hydrogeological models for our local watersheds, estimated source terms for wastewater treatment plants, and utility data on well mixing and water distribution to estimate historical PFOA, PFOS, and PFHpA concentrations in community water in the study area. Models for estimating the water concentrations at participants' homes and workplaces will be validated by analysis of PFAS in tap water samples, and used to estimate historical monthly PFAS doses for each study participant. Pharmacokinetic models will be developed for perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), perfluorononanoate (PFNA), perfluorohexanesulfonate (PFHxS), perfluoroheptanoate (PFHpA), and perfluorobutanesulfonate (PFBS), and validated by comparison of nationwide measurements of these PFAS chemicals in public water systems, collected from 2013-2015 under EPA's Third Unregulated Contaminant Monitoring Rule, to individual serum measurements from the National Biomonitoring Program. These pharmacokinetic models and estimated doses for each participant will be used to obtain modelled serum PFAS concentrations over time for each participant. Bayesian pharmacokinetic calibration of modelled serum PFAS concentrations, and non-parametric epidemiological analysis of PFAS exposure mixtures, will also be conducted when appropriate. This study will help address the key policy question of whether people served by water systems with PFAS detections are at greater risk of adverse health effects than those who do not have PFAS in their water, after accounting for other known risk factors. It will also provide useful information regarding the extent to which PFAS in drinking water contributes to overall exposure and biomonitoring results for these chemicals in a nationally representative sample.